Novartis Cosentyx sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data Ruby Khatun Khatun21 Sep 2017 4:27 AM GMTBasel, September 13, 2017 - Novartis announced, first of its kind Phase III data showing Cosentyx® (secukinumab) delivered high and long-lasting skin...